No country explicitly permits heritable genome editing, but the bans come as treaties, crimes, licences and a US budget rider. This piece compares them and maps what would have to change.
Is human germline gene editing legal? The short answer most people expect is “no, it is banned everywhere,” and that answer is roughly right while being wrong in ways that matter. When the Shenzhen researcher He Jiankui announced in late 2018 that twin girls had been born from embryos he had edited, there was no single global law he had broken. A Chinese court did sentence him to three years in prison in December 2019, but under a general offense of illegal medical practice that many legal experts thought was a stretch (Shao 2021).
That gap is the subject here. Nobody has settled what the legal status of heritable editing actually is across the world, partly because the rules come in incompatible forms: criminal statutes, licensing regimes, a treaty, a budget rider, ministry guidelines. Some countries say nothing. This article sets out what is established, the competing readings of the patchwork, and an analysis built for this piece of what a clinic would have to change, country by country, before it could lawfully start a pregnancy with an edited embryo.
This is general information about law and policy, not legal advice.
Germline, heritable, and why the vocabulary decides the answer
Two terms get blurred constantly. Germline editing means changing the DNA of embryos, eggs, sperm or their precursor cells. Heritable editing is narrower: using such a cell or embryo to start a pregnancy, so the change can pass to future generations. If the mechanics of the tools are unfamiliar, the x9m8 explainer on how CRISPR works covers the basics.
The distinction is not pedantry. In the most complete published survey of national policies, Françoise Baylis and colleagues counted the two practices separately and got very different pictures (Baylis et al. 2020). Nearly all explicit prohibitions target reproduction, not research.
The question is live outside academia too. After China changed its criminal code, one outlet ran the headline “Can China’s New Criminal Law Deter the Next He Jiankui?” (Shao 2021), and lawyers have argued in print over the reach of the main US restriction.
What is established: the global count
Baylis et al. (2020), published in The CRISPR Journal, surveyed 106 countries and found relevant policy documents in 96. Of those 96, 75 prohibit using a genetically modified embryo to start a pregnancy: 70 outright and 5 with exceptions. Three were indeterminate and 18 had no relevant policy the authors could find. The headline sentence from the paper’s summary is blunt:
“No country explicitly permits heritable human genome editing.”
Baylis, Darnovsky, Hasson and Krahn, 2020
Germline research without a pregnancy looks completely different in the same dataset. Only 23 countries prohibit it (19 outright, 4 with exceptions), 11 permit it, 6 are indeterminate, and 56 have no relevant information.
Two caveats apply. The survey predates China’s criminal amendment, so it is a snapshot. And “prohibit” lumps together a prison term, a licensing condition and a limit on a regulator’s budget, which count the same in a tally but behave very differently.
International soft law points the same way. The international commission convened by the US National Academies and the UK’s Royal Society concluded in 2020 that heritable editing “should not be used to create a pregnancy until it is established that precise genomic changes can be made reliably” (International Commission 2020). The World Health Organization followed with a governance framework in July 2021 (WHO 2021). Neither is binding.
Five legal regimes up close
United States: a ban written as a spending limit
No federal statute makes heritable editing a crime. The barrier is an appropriations rider that has ridden on FDA funding bills since December 2015, when Representative Robert Aderholt introduced it; a House subcommittee dropped it in May 2019 and the full Appropriations Committee restored it by voice vote weeks later (STAT, republished by Scientific American, 2019). The rider forbids the FDA from using funds to acknowledge an investigational application for research “in which a human embryo is intentionally created or modified to include a heritable genetic modification.” Baylis et al. (2020) locate it in the Further Consolidated Appropriations Act of 2020. It appears again as Section 734 of the House’s FY2027 agriculture and FDA bill, which passed the House on June 4, 2026, according to an analysis by FDA regulatory lawyers (Newberger et al. 2026).
Its scope is contested. In a 2021 exchange in the Journal of Law, Medicine & Ethics, Kerry Lynn Macintosh argued that the rider also catches embryos made from edited sperm or eggs, while I. Glenn Cohen, Jacob Sherkow and Eli Adashi replied that an embryo exists only after fertilization, so gamete editing falls outside the text (Macintosh, Cohen, Sherkow and Adashi 2021). Both sides agreed the rider deserves reconsideration.
The Oviedo Convention: a treaty ban in Europe
The Council of Europe’s Convention on Human Rights and Biomedicine, opened for signature at Oviedo on 4 April 1997 (ETS No. 164), contains the clearest binding text anywhere (Council of Europe 1997). Article 13 reads:
“An intervention seeking to modify the human genome may only be undertaken for preventive, diagnostic or therapeutic purposes and only if its aim is not to introduce any modification in the genome of any descendants.”
Convention on Human Rights and Biomedicine, Article 13 (1997)
Article 18(2) separately states that “The creation of human embryos for research purposes is prohibited.” Baylis et al. (2020) count 29 ratifying states, each one counted as prohibiting heritable editing, plus six that signed without ratifying. The treaty forbids the outcome; it does not attach a penalty, which ratifying states have to supply in domestic law.
United Kingdom: licensing with one engineered exception
British law works through the Human Fertilisation and Embryology Act 1990. Section 3(2) provides that “No person shall place in a woman” an embryo “other than a permitted embryo” (HFE Act 1990, s. 3). Section 3ZA then defines a permitted embryo as one in which no nuclear or mitochondrial DNA of any cell has been altered (HFE Act 1990, s. 3ZA).
The interesting part is subsection (5). It lets regulations treat an egg or embryo as permitted when a prescribed process designed to prevent transmission of serious mitochondrial disease has been applied. That is the legal door for mitochondrial donation, a technique that changes which mitochondrial DNA a child inherits without editing a gene in the usual sense (the x9m8 piece on why mitochondrial DNA comes from your mother explains the biology). Nuclear genome editing has no equivalent exception.
China: from guidelines to a criminal offense
Before 2019, Chinese rules were mostly administrative. The Law Library of Congress summarized them shortly after the twins’ births: 2003 ethics guidelines from the science and health ministries banned implanting genetically modified research embryos into a human or animal reproductive system, the assisted-reproduction technical standards banned “genetic manipulation of human embryos for reproductive purposes,” and the 2003 guidelines carried no penalties at all (Law Library of Congress 2018).
Writing in the Hastings Bioethics Forum, Ruipeng Lei and Renzong Qiu called it “regrettable” that the case was reduced to illegal medical practice (Lei and Qiu 2020). The legislature then acted. Criminal Law Amendment XI, adopted in December 2020, created an offense of illegally implanting gene-edited or cloned human embryos into human or animal bodies, with up to seven years in prison, effective March 1, 2021 (China Daily 2020; Shao 2021). A law firm’s summary of the draft described the offense as implantation “in violation of relevant State regulations,” punishable by imprisonment and a fine (Morrison Foerster, undated). Chinese scholars still debate what the new crime protects; Ye Liangfang argues it is the order of medical and health administration (Ye 2022).
Canada and the rest
Canada’s Assisted Human Reproduction Act lists among its prohibited procedures any act to “alter the genome of a cell of a human being or in vitro embryo” such that “the alteration is capable of being transmitted to descendants” (Assisted Human Reproduction Act, s. 5(1)(f)). The wording reaches any human cell, so research is caught too. The same survey codes Australia and Russia as prohibiting heritable editing, Japan as permitting embryo research but prohibiting reproduction, and South Africa as having no relevant policy identified in either category.
Three competing readings of the patchwork
Reading 1: a de facto global ban
The case for it: no country permits the practice, most countries with any policy prohibit it, the major scientific bodies have said not yet, and the one known violator went to prison. Legal variety, on this view, is cosmetic.
The case against: “no country permits” is compatible with many countries having no rule. Eighteen of the 96 countries with documents, plus the ten surveyed countries without any, sit outside the prohibition column (Baylis et al. 2020). And the He prosecution needed a general offense, which tells you the specific law was missing.
Reading 2: a patchwork with exploitable gaps
Supporters point to the US rule, which limits a regulator’s budget rather than the conduct and must be renewed each funding cycle; to the gamete argument in the JLME exchange; and to the silent countries. Fertility patients already travel for treatment, so a gap anywhere is a gap for anyone with a passport.
Against it: a gap in the text is not a gap in practice. Clinics need staff, ethics approvals, insurers and a place to publish, and each is a choke point with or without a gene-editing statute.
Reading 3: the bans are provisional
The international commission’s report describes a pathway for countries that decide to allow clinical use, and the UK’s mitochondrial exception proves a legislature can carve a narrow route through a germline rule. On this view current law is a moratorium written in statute, and the real question is which jurisdiction moves first, and for which disease.
Against it: the safety barrier is scientific, not only legal. Unintended edits, mosaicism and the difficulty of checking every cell of an embryo are unresolved problems, as the x9m8 review of how off-target effects are measured describes. Embryo screening already serves most couples at risk of passing on a single-gene disease, which weakens the medical case for editing.
A comparative table built for this article
The table codes each regime by instrument, trigger and the sanction stated in the sources consulted. Where a source gave no penalty, the cell says so.
| Jurisdiction | Instrument | What triggers it | Sanction in sources seen | Covers research-only editing? |
|---|---|---|---|---|
| United States | Annual FDA appropriations rider (Sec. 734 in House FY2027 bill) | FDA acknowledging an IND for research creating or modifying an embryo with a heritable modification | No criminal penalty in the rider; trial cannot lawfully proceed without FDA review | No (federal funding limits apply separately) |
| Oviedo ratifying states (29 per Baylis et al.) | Treaty, Art. 13 | Any genome intervention aimed at modifying descendants’ genomes | Left to national law | Not by Art. 13; Art. 18(2) bars creating embryos for research |
| United Kingdom | HFE Act 1990, ss. 3 and 3ZA | Placing in a woman an embryo whose nuclear or mitochondrial DNA was altered | Not stated in sections consulted | Licensed research permitted (not detailed here) |
| China | Criminal Law (Amendment XI), in force March 1, 2021; earlier ministry rules | Implanting gene-edited or cloned embryos into a human or animal body | Up to 7 years’ imprisonment | Research guidelines permit under 14-day limit and ethics review |
| Canada | Assisted Human Reproduction Act, s. 5(1)(f) | Altering a human cell or embryo so the change can be transmitted | Penalty section not retrieved | Yes, wording covers any human cell |
| Japan, Australia, Russia | National rules (mechanism not examined here) | Reproductive use of edited embryos | Not examined | Japan permits; others not identified (Baylis et al.) |
| South Africa and others | No relevant policy identified in 2020 survey | None specific | General medical and research law only | None specific |
Scenario analysis: what a clinic would need to change
Suppose a clinic wanted to correct a disease-causing variant in an embryo and transfer it, openly and lawfully, with no hidden step. What would have to happen first in each place? The analysis below is the author’s doctrinal reading of the provisions quoted above. It identifies the minimum legal change, not whether the change is likely or wise.
- United States. Congress would have to pass an FDA appropriations act without the rider, since it has to be renewed each cycle anyway. The FDA would then need to accept and clear an investigational application, with institutional review and any state-law hurdles still in place. The gamete argument offers no shortcut: even if the rider did not apply, ordinary FDA review would. Legal change needed: a legislative omission, one budget cycle.
- Oviedo ratifying state. Article 13 forbids the aim itself, so no licence can authorize it while the state remains bound. Legal change needed: leaving or amending the treaty, then legislation. The highest bar in the table.
- United Kingdom. Section 3ZA(5) only authorizes regulations for serious mitochondrial disease. Editing nuclear DNA would need Parliament to amend the definition of a permitted embryo, then the fertility regulator to license specific treatments. Legal change needed: primary legislation, followed by licensing.
- China. Implantation is a crime. Because the offense, as summarized from the draft, turns on violating relevant State regulations, a future regulation authorizing controlled use might arguably narrow criminal exposure. That is untested. Legal change needed: at least new national regulations, and realistically a criminal-law amendment.
- Canada. The ban sits in a criminal statute and covers research as well. Legal change needed: an Act of Parliament.
- A country with no specific rule. The lowest legal bar, not zero: general medical, research-ethics and fraud law remain, and China’s 2019 case shows general offenses can be stretched. Exposure is unpredictable.
What this shows: the barriers sort into four tiers by how hard they are to remove. A budget rider sits at the bottom, statutory licensing schemes next, criminal statutes above that, and a human-rights treaty at the top. It does not show how likely any change is, how courts would rule, or anything about safety. Ease of repeal also says nothing about enforcement: the US rider has survived every cycle since 2015.
The author’s reading, and what would settle it
Opinion, clearly labeled. The accurate one-line answer is that heritable human genome editing is not lawful anywhere that has addressed it, and that the reason differs enough between countries to matter. Reading 1 is right about the present. Reading 3 is right about the structure: most prohibitions are drafted as conditions that a legislature could lift, and the UK’s mitochondrial carve-out is a working template. Reading 2 overstates textual gaps, though the rider’s need for annual renewal is a real, under-discussed weak point.
Several developments would settle parts of this. On somatic editing’s move toward individualized treatment, see the x9m8 account of personalized gene editing after Baby KJ; pressure on germline rules is likely to follow the somatic success stories rather than precede them.
- A repeat of the Baylis et al. survey. Prediction: zero countries will be coded as permitting heritable editing.
- A court ruling or FDA statement on whether the rider reaches edited gametes. Prediction: no test case while the rider is renewed.
- A published Chinese prosecution under the 2021 offense. Its reasoning would show whether “relevant State regulations” carries real weight.
- Any Oviedo state proposing an exception to Article 13. Prediction: none within five years.
- A UK consultation on extending section 3ZA(5) beyond mitochondrial disease, the most plausible first legal opening anywhere.
Common questions
Did He Jiankui break a law against gene editing?
Not a specific one, because none existed in China at the time. He was convicted in December 2019 of illegal medical practice and sentenced to three years in prison (Shao 2021). China created a specific crime of implanting gene-edited embryos only in the amendment that took effect in March 2021.
Is it legal to edit human embryos for research in the US?
Federally, yes, if no pregnancy is started; Baylis et al. (2020) code the US as permitting such research while restricting federal funding. Some states restrict particular embryo research, so location matters.
Is mitochondrial donation a form of germline editing?
It changes which mitochondrial DNA a child inherits, so UK law needed a specific exception in section 3ZA(5). It does not rewrite nuclear genes, which is why it is usually treated separately from CRISPR editing.
Could someone travel to a country with no law to do it?
In principle the legal barrier there is lower, but not absent. General medical and research laws still apply, and the He case shows prosecutors can use broad offenses.
Further reading
- CRISPR People: The Science and Ethics of Editing Humans by Henry T. Greely. A law professor's book-length account of the He Jiankui affair and its legal aftermath. See it on Amazon (affiliate link)
- The Code Breaker: Jennifer Doudna, Gene Editing, and the Future of the Human Race by Walter Isaacson. A widely read narrative history of CRISPR that covers the He Jiankui births and the policy response. See it on Amazon (affiliate link)
As an Amazon Associate I earn from qualifying purchases. A commission may be earned if you buy through this link, at no extra cost to you.
References
- Baylis, F., Darnovsky, M., Hasson, K., & Krahn, T. M. (2020). Human germ line and heritable genome editing: the global policy landscape. The CRISPR Journal. doi:10.1089/crispr.2020.0082. Full text; summary page.
- Council of Europe. (1997). Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (ETS No. 164), Oviedo, 4 April 1997. rm.coe.int/168007cf98.
- Human Fertilisation and Embryology Act 1990 (UK), section 3. legislation.gov.uk.
- Human Fertilisation and Embryology Act 1990 (UK), section 3ZA. legislation.gov.uk.
- Assisted Human Reproduction Act, S.C. 2004, c. 2 (Canada), section 5. laws-lois.justice.gc.ca.
- Macintosh, K. L., Cohen, I. G., Sherkow, J. S., & Adashi, E. Y. (2021). Letter to the editor [exchange on the FDA heritable-modification rider]. Journal of Law, Medicine & Ethics, 49(1), 156-157. doi:10.1017/jme.2021.21. Cambridge Core.
- STAT (2019, June 4). Congress revives ban on altering the DNA of human embryos used for pregnancies. Republished by Scientific American. scientificamerican.com.
- Newberger, J. D., Koblitz, S. W., Livornese, D. L., Levy, D. K., Tobolowsky, M. A., Richardson, K. E., van Laack, R., & Bass, M. (2026, June 24). Riders on the storm part 1: what the FY2027 appropriations report means for FDA. FDA Law Blog (Hyman, Phelps & McNamara). thefdalawblog.com.
- Law Library of Congress. (2018, December). On gene-edited babies: what Chinese law says. In Custodia Legis. blogs.loc.gov.
- Lei, R., & Qiu, R. (2020, January 4). Chinese bioethicists: He Jiankui’s crime is more than illegal medical practice. Hastings Bioethics Forum. thehastingscenter.org.
- Shao, B. (2021, March 12). Can China’s new criminal law deter the next He Jiankui? Sixth Tone. sixthtone.com.
- China Daily. (2020, December 29). China ups IPR protection, lowers criminal liability age in new law amendment. chinadaily.com.cn.
- Morrison Foerster. (n.d.). China to criminalize human genetic resources violations. lifesciences.mofo.com.
- Ye, L. (2022). On the legal interest of illegally implanting gene-edited or cloned embryos: from the perspective of bioethics. Journal of Zhejiang University (Humanities and Social Sciences), 52(7), 34-48. doi:10.3785/j.issn.1008-942X.CN33-6000/C.2022.02.104. zjujournals.com.
- International Commission on the Clinical Use of Human Germline Genome Editing (National Academy of Medicine, National Academy of Sciences, Royal Society). (2020). Heritable Human Genome Editing. National Academies Press. doi:10.17226/25665. nap.nationalacademies.org.
- World Health Organization. (2021, July 12). Human genome editing: a framework for governance. who.int.
